The DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.
Medication Treatment of Opioid Use Disorder
Open accessAbstract
Opioid use disorder (OUD) is a chronic, relapsing condition, often associated with legal, interpersonal, and employment problems. Medications demonstrated to be effective for OUD are methadone (a full opioid agonist), buprenorphine (a partial agonist), and naltrexone (an opioid antagonist). Methadone and buprenorphine act by suppressing opioid withdrawal symptoms and attenuating the effects of other opioids. Naltrexone blocks the effects of opioid agonists. Oral methadone has the strongest evidence for effectiveness. Longer duration of treatment allows restoration of social connections and is associated with better outcomes. Treatments for OUD may be limited by poor adherence to treatment recommendations and by high rates of relapse and increased risk of overdose after leaving treatment. Treatment with methadone and buprenorphine has the additional risk of diversion and misuse of medication. New depot and implant formulations of buprenorphine and naltrexone have been developed to address issues of safety and problems of poor treatment adherence. For people with OUD who do not respond to these treatments, there is accumulating evidence for supervised injectable opioid treatment (prescribing pharmaceutical heroin). Another medication mode of minimizing risk of overdose is take-home naloxone. Naloxone is an opioid antagonist used to reverse opioid overdose, and take-home naloxone programs aim to prevent fatal overdose. All medication-assisted treatment is limited by lack of access and by stigma. In seeking to stem the rising toll from OUD, expanding access to approved treatment such as methadone, for which there remains the best evidence of efficacy, may be the most useful approach.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence
Mattick, R. P., Breen, C., Kimber, J., & Davoli, M. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002207.pub4 · Cited by 2,274
Neonatal Abstinence Syndrome after Methadone or Buprenorphine Exposure
Jones, H. E., Kaltenbach, K., Heil, S. H., Stine, S. M., Coyle, M. G., Arria, A. M., O'Grady, K. E., Selby, P., Martin, P. R., & Fischer, G. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1005359 · Cited by 986
A 33-Year Follow-up of Narcotics Addicts
Hser, Y.-I., Hoffman, V., Grella, C. E., & Anglin, M. D. (2001) · Archives of General Psychiatry · doi:10.1001/archpsyc.58.5.503 · Cited by 848
Lee, J. D., Nunes, E. V., Novo, P., Bachrach, K., Bailey, G. L., Bhatt, S., Farkas, S., Fishman, M., Gauthier, P., Hodgkins, C. C., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)32812-x · Cited by 700
Sun, E. C., Dixit, A., Humphreys, K., Darnall, B. D., Baker, L. C., & Mackey, S. (2017) · BMJ · doi:10.1136/bmj.j760 · Cited by 534
McDonald, R., & Strang, J. (2016) · Addiction · doi:10.1111/add.13326 · Cited by 471
Self-citationHser, Y., Saxon, A. J., Huang, D., Hasson, A., Thomas, C., Hillhouse, M., Jacobs, P., Teruya, C., McLaughlin, P., Wiest, K., et al. (2014) · Addiction · doi:10.1111/add.12333 · Cited by 455
Torsade de Pointes Associated with Very-High-Dose Methadone
Krantz, M. J., Lewkowiez, L., Hays, H., Woodroffe, M. A., Robertson, A. D., & Mehler, P. S. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-137-6-200209170-00010 · Cited by 426
Methadone maintenance at different dosages for opioid dependence
Faggiano, F., Vigna-Taglianti, F., Versino, E., & Lemma, P. (2003) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002208 · Cited by 406
McLellan, A. T., McKay, J. R., Forman, R., Cacciola, J., & Kemp, J. (2005) · Addiction · doi:10.1111/j.1360-0443.2005.01012.x · Cited by 389
Cited by
Retention of patients in opioid substitution treatment: A systematic review
O’Connor, A. M., Cousins, G., Durand, L., Barry, J., & Boland, F. (2020) · PLOS ONE · doi:10.1371/journal.pone.0232086 · Cited by 298
Powers, N., Massena, C., Crouse, B., Smith, M., Hicks, L., Evans, J. T., Miller, S., Pravetoni, M., & Burkhart, D. (2023) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.3c00347 · Cited by 15
Gold, M. S., Blum, K., Bowirrat, A., Pinhasov, A., Bagchi, D., A. Dennen, C., K. Thanos, P., Hanna, C., Lewandrowski, K.-U., Sharafshah, A., et al. (2024) · INNOSC Theranostics and Pharmacological Sciences · doi:10.36922/itps.1918 · Cited by 9
Metadata
- Authors
- Bell, J., & Strang, J.
- Venue
- Biological Psychiatry
- Publisher
- Elsevier BV
- Published
- 2020-01
- Volume
- 87
- Issue
- 1
- Pages
- 82-88
- ISSN
- 0006-3223 (ISSN-L)
- OpenAlex
- W2956150492
- Cited by
- 328
- References
- 64
- FWCI
- 22.67
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Medication Treatment of Opioid Use Disorder. https://app.cochat.ai/papers/10.1016/j.biopsych.2019.06.020
- The paper
- Bell, J., & Strang, J. (2020). Medication Treatment of Opioid Use Disorder. Biological Psychiatry. https://doi.org/10.1016/j.biopsych.2019.06.020
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
